Published in Semin Thromb Hemost on June 01, 2004
Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe (2008) 1.34
The chemokine network. I. How the genomic organization of chemokines contains clues for deciphering their functional complexity. Clin Exp Immunol (2007) 1.14
Role of platelets in neuroinflammation: a wide-angle perspective. J Neuroinflammation (2010) 1.11
Platelet factor 4 limits Th17 differentiation and cardiac allograft rejection. J Clin Invest (2014) 0.97
Platelet factor 4 regulation of monocyte KLF4 in experimental cerebral malaria. PLoS One (2010) 0.91
Mechanism of platelet factor 4 (PF4) deficiency with RUNX1 haplodeficiency: RUNX1 is a transcriptional regulator of PF4. J Thromb Haemost (2011) 0.90
Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm (2010) 0.90
Platelet factor 4 mediates vascular smooth muscle cell injury responses. Blood (2013) 0.86
Collagen can selectively trigger a platelet secretory phenotype via glycoprotein VI. PLoS One (2014) 0.80
An unexpected role for platelets in blocking Th17 differentiation. J Clin Invest (2014) 0.80
Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia. Thromb J (2013) 0.79
Platelet factor 4 is highly upregulated in dendritic cells after severe trauma. Mol Med (2009) 0.77
Differential proteomic analysis of virus-enriched fractions obtained from plasma pools of patients with dengue fever or severe dengue. BMC Infect Dis (2015) 0.76
Platelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral Attachment. AIDS Res Hum Retroviruses (2016) 0.75
International consensus report on the investigation and management of primary immune thrombocytopenia. Blood (2009) 7.72
CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity (2010) 2.16
Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med (2009) 2.15
Platelet- and megakaryocyte-derived microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4-HIV. AIDS (2003) 2.12
Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res (2004) 2.07
Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol (2003) 2.03
Elimination of platelet factor 4 (PF4) from platelets reduces atherosclerosis in C57Bl/6 and apoE-/- mice. Thromb Haemost (2007) 2.00
Platelet factor 4 localization in carotid atherosclerotic plaques: correlation with clinical parameters. Thromb Haemost (2003) 1.91
How I treat heparin-induced thrombocytopenia. Blood (2012) 1.85
Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006) 1.84
Control of megakaryocyte-specific gene expression by GATA-1 and FOG-1: role of Ets transcription factors. EMBO J (2002) 1.84
Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator. Circulation (2008) 1.84
Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood (2012) 1.72
NuRD mediates activating and repressive functions of GATA-1 and FOG-1 during blood development. EMBO J (2009) 1.66
Nuclear translocation of urokinase-type plasminogen activator. Blood (2008) 1.66
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood (2004) 1.63
Post-transcriptional regulation of urokinase-type plasminogen activator receptor expression in lipopolysaccharide-induced acute lung injury. Am J Respir Crit Care Med (2008) 1.62
Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood (2003) 1.62
Dynamic antibody-binding properties in the pathogenesis of HIT. Blood (2012) 1.59
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood (2005) 1.59
In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood (2003) 1.53
Rational design and characterization of platelet factor 4 antagonists for the study of heparin-induced thrombocytopenia. Blood (2012) 1.50
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood (2004) 1.50
How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood (2012) 1.40
The kinetics of αIIbβ3 activation determines the size and stability of thrombi in mice: implications for antiplatelet therapy. Blood (2010) 1.40
Infusion of mature megakaryocytes into mice yields functional platelets. J Clin Invest (2010) 1.39
Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci (2006) 1.38
Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program (2004) 1.38
The clinical course and genetic defect in the PCFT gene in a 27-year-old woman with hereditary folate malabsorption. J Pediatr (2008) 1.36
Platelet factor 4 mediates inflammation in experimental cerebral malaria. Cell Host Microbe (2008) 1.34
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood (2007) 1.34
Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots. Blood (2008) 1.31
ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood (2003) 1.28
Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization. Blood (2007) 1.28
LRP and alphavbeta3 mediate tPA activation of smooth muscle cells. Am J Physiol Heart Circ Physiol (2006) 1.26
Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction. J Biol Chem (2002) 1.26
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. Thromb Res (2009) 1.25
Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol (2006) 1.25
Maturation stage-specific regulation of megakaryopoiesis by pointed-domain Ets proteins. Blood (2006) 1.25
Determinants of PF4/heparin immunogenicity. Blood (2007) 1.25
Megakaryocyte biology and related disorders. J Clin Invest (2005) 1.23
Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Brain Res Dev Brain Res (2005) 1.23
Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood (2002) 1.21
uPA modulates the age-dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab (2008) 1.18
Antithrombotic thrombocytes: ectopic expression of urokinase-type plasminogen activator in platelets. Blood (2003) 1.18
Regulation of neovascularization by human neutrophil peptides (alpha-defensins): a link between inflammation and angiogenesis. FASEB J (2004) 1.17
Platelet factor 4 activity against P. falciparum and its translation to nonpeptidic mimics as antimalarials. Cell Host Microbe (2012) 1.16
Human alpha-defensin regulates smooth muscle cell contraction: a role for low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. Blood (2002) 1.16
Blood clearance and activity of erythrocyte-coupled fibrinolytics. J Pharmacol Exp Ther (2004) 1.16
CXC chemokine ligand 4 (Cxcl4) is a platelet-derived mediator of experimental liver fibrosis. Hepatology (2010) 1.15
Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature. Blood (2007) 1.14
Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Blood (2010) 1.14
Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood (2005) 1.13
Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb Haemost (2006) 1.12
Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J Biol Chem (2004) 1.12
Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis. Blood (2006) 1.11
Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood (2013) 1.11
Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke (2005) 1.11
Neutrophil alpha-defensins cause lung injury by disrupting the capillary-epithelial barrier. Am J Respir Crit Care Med (2010) 1.10
FOG1 requires NuRD to promote hematopoiesis and maintain lineage fidelity within the megakaryocytic-erythroid compartment. Blood (2010) 1.09
The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood (2005) 1.09
uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res (2008) 1.09
Challenges and promises for the development of donor-independent platelet transfusions. Blood (2013) 1.09
Expression, purification and characterization of human glutamate dehydrogenase (GDH) allosteric regulatory mutations. Biochem J (2002) 1.08
In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood (2010) 1.08
Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis. J Pharmacol Exp Ther (2009) 1.05
Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia. Blood (2010) 1.04
Critical role of integrin alpha 5 beta 1 in urokinase (uPA)/urokinase receptor (uPAR, CD87) signaling. J Biol Chem (2003) 1.03